Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weiru Wang

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Cancer Cell|December 8, 2009
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activationBijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
ACS Medicinal Chemistry Letters|January 21, 2022
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)Bryan K Chan, Eileen Seward, Michael Lainchbury, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1John C Tellis, BinQing Wei, Michael Siu, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
Nature|August 17, 2012
Recurrent R-spondin fusions in colon cancerSomasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Cancer Cell|December 8, 2009
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activationBijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
ACS Medicinal Chemistry Letters|January 21, 2022
Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)Bryan K Chan, Eileen Seward, Michael Lainchbury, et al.
ACS Medicinal Chemistry Letters|September 18, 2024
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1John C Tellis, BinQing Wei, Michael Siu, et al.
Journal of Medicinal Chemistry|July 18, 2013
Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitorsXiaozhang Zheng, Paul Bauer, Timm Baumeister, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2015
Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubilityMark Zak, Bianca M Liederer, Deepak Sampath, et al.
Nature|August 17, 2012
Recurrent R-spondin fusions in colon cancerSomasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
Pageof 10